Here are the S-3 shelf registrations from Arcus Biosciences, Inc. (RCUS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow RCUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RCUS filings page.
Arcus Biosciences, Inc. files a shelf registration and establishes an at-the-market equity program to sell up to $200,000,000 of common stock. Sales may occur from time to time after the effective date under an equity distribution agreement with Leerink Partners LLC as sales agent and may be conducted on the New York Stock Exchange or other markets as at-the-market offerings.
As context, Arcus reported 125,294,769 shares outstanding as of December 31, 2025, and its last reported NYSE sale price was $18.85 per share on February 23, 2026.